Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-0616-013
2022-502777-42-00Phase 3Withdrawn
- Sponsor
- Merck & Co.
- Start
- Sep 2023
- Modality
- Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial in hypercholesterolemia comparing MK-0616 with Placebo (2 arms). Primary endpoints: Percent change from baseline in LDL-C at Week 24, Number of participants who experience one or more adverse events and 1 more. Planned start Sep 2023; status: withdrawn.
02
Drugs
enlicitide
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on 2022-502777-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502777-42-00.